Our results showed that adjuvant therapy with aromatase inhibitors of breast cancer women is associated with increased risk of heart failure and combined CV events, and such therapy probably amplifies the “intrinsic” CV risk of the patient. This evidence concerns the gene CYP19A1 and breast cancer.